BVXV - BiondVax Pharmaceuticals Ltd.
| Previous Close | 5.65 |
| Open | 5.55 |
| Bid | 5.25 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 5.55 - 5.55 |
| 52 Week Range | 3.51 - 7.26 |
| Volume | 2,100 |
| Avg. Volume | 6,186 |
| Market Cap | 36.319M |
| Beta (3Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
- PR Newswire
BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
JERUSALEM, Oct. 7, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine candidate, announced today the receipt of €4 million from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "This past June we were honored to welcome EIB Vice-President Mr. Ambroise Fayolle to our manufacturing facility in Jerusalem for a signature event celebrating the extension of the EIB-BiondVax financing agreement to €24 million.
- PR Newswire
BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
JERUSALEM , Aug. 28, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- Zacks Small Cap Research
BVXV: Raises $20 Million; Phase 3 Trial Fully Funded…
On July 16, 2019, BiondVax Pharmaceuticals Ltd. (BVXV) announced that the previously announced rights offering was fully subscribed and the company raised gross proceeds of $20 million through the sale of 3,057,466 American Depository Shares (ADSs) and 18,298,898 ordinary shares. BiondVax’s largest shareholder, Angels Investment High Tech Ltd. (which is wholly owned by Mr. Marius Nacht), fully subscribed for the entire allotment available to them and also exercised the option to purchase 2,203,640 ADSs and 141,538 ordinary shares that were not purchased by other shareholders. Thus, Angels Investment High Tech Ltd. total investment in the rights offering was $16.67 million, and the firm is now a controlling shareholder with a holding of approximately 42% of BiondVax.
- PR Newswire
BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
JERUSALEM, Israel, July 16, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) is proud to announce today the results of its previously announced rights offering. The Company has received subscriptions from existing shareholders for all the offered American Depositary Shares ("ADSs") and ordinary shares, being a total of 3,057,466 ADSs and 18,298,898 ordinary shares, raising total gross proceeds of US$20 Million.
- PR Newswire
First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
JERUSALEM, July 8, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate frequently and unpredictably, and the strains that dominate often vary in time and place. For example, according to the CDC, the first part of the 2018/19 flu season was dominated by H1 strains throughout most of the continental USA, while the south-east USA was dominated by an H3 strain.
- PR Newswire
European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million
JERUSALEM, June 26, 2019 /PRNewswire/ -- The Board of Directors and Management of BiondVax Pharmaceuticals Ltd. (BVXV), was honored to host Mr. Ambroise Fayolle, Vice-President of the European Investment Bank (EIB), during his visit to BiondVax's new mid-size commercial scale manufacturing facility in Israel.
- Investopedia
BiondVax Gets OK to Build Plant in Israel (BVXV)
BiondVax Pharmaceuticals Ltd. (BVXV) secured a grant from the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, to build a manufacturing facility for the production of Phase 3 and commercial batches of its universal flu vaccine, M-001. Influenza viruses often undergo changes to certain surface proteins which results in development of new virus strains that are unfamiliar to the human body immune system. The bigger the surface protein change, the lower the possibility of body’s immune system to fight against the disease.
- PR Newswire
Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
JERUSALEM, June 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that a patent covering production processes of the Company's M-001 universal influenza vaccine candidate was allowed in the USA and Japan. Titled "Compositions of multimeric-multiepitope influenza polypeptides and their production" the patent, which is pending in Europe, covers the unique composition and manufacturing processes of M-001. Designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza, the vaccine has been shown to be safe, well-tolerated, and immunogenic to a broad range of flu strains in clinical trials.
- Zacks Small Cap Research
BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results…
With the company set to enter the second enrollment season for the ongoing Phase 3 clinical trial of its universal influenza vaccine M-001, a rights offering has recently been initiated in which the company is looking to raise approximately $20 million. The terms of the rights offering allow for each shareholder and American Depositary Share (ADS) holder to receive approximately 0.54 subscription rights for each 1 ADS or share owned. In exchange, Angels Investment asked that its affiliate, aMoon2 Fund Limited Partnership, be given the option to purchase any units offered but not purchased by other shareholders, but not less than $10 million combined between Angels Investment and aMoon2.
- PR Newswire
BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
JERUSALEM, Israel, June 10, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced a rights offering to holders of the Company's American Depositary Shares ("ADSs"). Proceeds from the rights offering will be used to fund operations including completion of the ongoing pivotal, clinical efficacy Phase 3 trial of BiondVax's M-001 universal flu vaccine candidate, and scale up of the M-001 production process in BiondVax's newly constructed mid-size manufacturing facility.
- PR Newswire
BiondVax Announces First Quarter 2019 Financial Results
JERUSALEM , May 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine ...
- PR Newswire
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel. Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.
- PR Newswire
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
JERUSALEM , April 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently ...
- PR Newswire
European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
JERUSALEM, April 22, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to extend the 2017 financing agreement with BiondVax by an additional €4 million. The funds will be used in support of the ongoing pivotal, clinical efficacy, Phase 3 trial of BiondVax's M-001 Universal Flu Vaccine candidate in Europe. The original €20 million EIB-BiondVax non-dilutive co-financing agreement was signed in June 2017 to support both construction of BiondVax's new mid-size commercial-scale manufacturing facility in Israel and the pivotal, clinical efficacy, Phase 3 trial in Europe.
- Zacks Small Cap Research
BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine…
BiondVax Pharmaceuticals Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).
- PR Newswire
BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
JERUSALEM, April 15, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that a patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate was accepted in Australia. Titled "Compositions of multimeric-multiepitope influenza polypeptides and their production" the patent application has been filed in eight other jurisdictions, and is under examination in Europe, China, Japan, and the USA. Dr. Tamar Ben-Yedidia, BiondVax's Chief Science Officer, commented, "Our five patent families cover multimeric-multiepitope polypeptides as well as composition, use, formulation and production aspects of M-001, BiondVax's Phase 3 universal flu vaccine candidate.
- PR Newswire
BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
JERUSALEM, March 28, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present next week at the Influenza Vaccines for the World conference in Edinburgh, Scotland, UK. Joshua Phillipson, BiondVax's Head of Business Development, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.
- PR Newswire
Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
JERUSALEM, March 21, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today that all participants have completed their final visit in a Phase 2 clinical trial conducted by several Vaccine Treatment and Evaluation Units (VTEUs) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health & Human Services (HHS)'s National Institutes of Health (NIH). 120 participants aged 18 to 49 years were enrolled at VTEUs at Baylor College of Medicine in Houston, Texas, the University of Iowa in Iowa City, Iowa, and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. Individuals were randomly assigned to receive either two doses of M-001 or two doses of a placebo, with the doses spaced three weeks apart.
- GlobeNewswire
Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire
BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
JERUSALEM, Nov. 26, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego. Dr. Ron Babecoff, BiondVax's Founder and CEO, will participate in a panel discussion and provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial. Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?
- Zacks Small Cap Research
BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine…
BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).
- PR Newswire
BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
JERUSALEM , Nov. 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- PR Newswire
BiondVax Announces Third Quarter 2018 Financial Results
JERUSALEM , Nov. 13, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- PR Newswire
BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
The 4,098 participants enrolled in this year's cohort will be monitored for two flu seasons. A second cohort of approximately 6,000 participants will be enrolled prior to the 2019/2020 flu season. Safety, as well as laboratory confirmed influenza incidence will be assessed, with results expected in the second half of 2020.
- PR Newswire
BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
JERUSALEM, Oct. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB). The first two tranches totaling €12 million were received by BiondVax earlier this year.
